22 active not recruiting. 22 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Active not recruiting 22 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis SAR442970, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Sanofi | 105 | 2025-07-07 | 2026-10-09 |
| A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis D-2570, Placebo - UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | InventisBio Co., Ltd | 120 | 2025-05-22 | 2026-07-17 |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Eltrekibart, Mirikizumab, Placebo - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 2 | Active not recruiting | Eli Lilly and Company | 143 | 2024-10-10 | 2026-10-07 |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis TAK-279, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Takeda | 213 | 2024-03-29 | 2026-08-17 |
| Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis emvistegrast, Placebo-to-match emvistegrast - Ulcerative Colitis | Phase 2 | Active not recruiting | Gilead Sciences | 228 | 2024-03-27 | 2026-04-09 |
| A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis Lutikizumab, Adalimumab - Ulcerative Colitis | Phase 2 | Active not recruiting | AbbVie | 156 | 2024-03-23 | 2025-10-07 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis Tilpisertib Fosmecarbil, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Gilead Sciences | 176 | 2023-12-05 | 2026-09-11 |
| Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics ALTB-268 - Ulcerative Colitis | Phase 2 | Active not recruiting | AltruBio Inc. | 50 | 2023-12-04 | 2026-05-05 |
| A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) Rosnilimab, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | AnaptysBio, Inc. | 132 | 2023-12-04 | 2025-10-03 |
| A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab)) Dupilumab, Placebo - Colitis Ulcerative | Phase 2 | Active not recruiting | Sanofi | 68 | 2023-01-12 | 2026-06-23 |
| A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B - Crohn Disease, Colitis, Ulcerative | Phase 2 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 247 | 2023-01-11 | 2026-10-06 |
| Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis SAR443122, Placebo - Colitis Ulcerative | Phase 2 | Active not recruiting | Sanofi | 187 | 2022-11-25 | 2026-04-27 |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab, Golimumab, JNJ-78934804 - Colitis, Ulcerative | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 577 | 2022-09-19 | 2026-09-28 |
| Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PL8177 Placebo, PL8177 - Ulcerative Colitis, Ulcerative Colitis Acute | Phase 2 | Active not recruiting | Palatin Technologies, Inc | 16 | 2022-09-15 | 2025-03-05 |
| Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis Hydroxychloroquine, Mesalamine - Ulcerative Colitis (Disorder) | Phase 1 / Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 3 | 2022-06-10 | 2025-02-11 |
| Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Active not recruiting | Abivax S.A. | 203 | 2021-12-03 | 2026-04-27 |
| Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection - Colorectal Carcinoma, Ulcerative Colitis | Phase 2 | Active not recruiting | Northwestern University | 42 | 2021-09-24 | 2026-01-21 |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Infliximab, Methylprednisolone, Prednisone - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Massachusetts General Hospital | 42 | 2020-08-31 | 2026-06-16 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2020-07-09 | 2026-07-15 |
Showing 20 of 22. Sign in to see all of them.
Colitis, Ulcerative (19) · Inflammatory Bowel Diseases (2) · Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Colitis, Microscopic (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Crohn Disease (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Digestive System Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Skin Neoplasms (1)
Gastroenteritis (22) · Colonic Diseases (21) · Digestive System Diseases (21) · Gastrointestinal Diseases (21) · Intestinal Diseases (21) · Inflammatory Bowel Diseases (17) · Neoplasms (3) · Neoplasms by Site (3) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2)
Infliximab (2) · guselkumab (2) · ABX464 (1) · Adalimumab (1) · Aquamin (1) · Atorvastatin (1) · Biopsy (1) · Budesonide (1) · CT-P13 (1) · Capsules (1) · Colonoscopy (1) · Disulfides (1) · Hydroxychloroquine (1) · Immunoglobulin G (1) · LDP-02 (1)
Sanofi (3) · Gilead Sciences (2) · Janssen Research & Development, LLC (2) · AbbVie (1) · Abivax S.A. (1) · AltruBio Inc. (1) · AnaptysBio, Inc. (1) · Eli Lilly and Company (1) · Icahn School of Medicine at Mount Sinai (1) · InventisBio Co., Ltd (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Muhammad N Aslam, MD (1) · Northwestern University (1) · Palatin Technologies, Inc (1)
United States (19) · Germany (12) · Poland (12) · Canada (11) · France (11) · Hungary (11) · Italy (11) · Japan (10) · Spain (10) · United Kingdom (10) · Czechia (9) · Austria (8) · Belgium (8) · Australia (7) · South Korea (7)
Bram Verstockt, MD (1) · Christopher Ma, MD MPH (1) · David Lin, MD, PhD (1) · Judy H Cho, MD (1) · Michael Dougan, MD, PHD (1) · Muhammad Nadeem Aslam (1) · Robert Jordan, VP Clinical Operations (1) · Stephen B Hanauer, MD (1) · Subra Kugathasan, MD (1)
PMID 37659673, PMID 38574740, PMID 39706209, PMID 40574492, PMID 41359652, PMID 41871904, PMID 42065421, PMID 42634341
2023 (5), 2018 (1), P30CA060553 (1), UG1CA242643 (1)